TCLI.F Stock Overview
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Theraclion SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.59 |
52 Week High | €0.59 |
52 Week Low | €0.59 |
Beta | 0.21 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -60.67% |
Recent News & Updates
Recent updates
Shareholder Returns
TCLI.F | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | -0.2% | 1.3% |
1Y | n/a | 10.6% | 29.8% |
Return vs Industry: Insufficient data to determine how TCLI.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how TCLI.F performed against the US Market.
Price Volatility
TCLI.F volatility | |
---|---|
TCLI.F Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TCLI.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TCLI.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 30 | Martin Deterre | https://www.theraclion.com |
Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient’s skin and optimizes the image quality. Theraclion SA was founded in 2004 and is based in Malakoff, France.
Theraclion SA Fundamentals Summary
TCLI.F fundamental statistics | |
---|---|
Market cap | US$16.73m |
Earnings (TTM) | -US$5.27m |
Revenue (TTM) | US$2.02m |
8.3x
P/S Ratio-3.2x
P/E RatioIs TCLI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TCLI.F income statement (TTM) | |
---|---|
Revenue | €1.87m |
Cost of Revenue | €4.04m |
Gross Profit | -€2.17m |
Other Expenses | €2.70m |
Earnings | -€4.88m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.11 |
Gross Margin | -116.29% |
Net Profit Margin | -260.94% |
Debt/Equity Ratio | 130.1% |
How did TCLI.F perform over the long term?
See historical performance and comparison